# Consensus checked against original sources: Chromatin Accessibility = Transcriptional Competence

Cutoff: 9 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.

## EP400 compensation: accessibility and expression recovery
Provider said this original was unavailable. Actual original Results1/2/6/8/25/26 show early SWI/SNF inhibition loses accessibility and transcription; EP400 restores both at many promoters. Above-control ATAC in clusters3/4 does not yield broadly above-control transcription. Do not describe every recovered promoter as failing expression recovery or provider search absence as a field gap. [Original PMID37922899](https://pubmed.ncbi.nlm.nih.gov/37922899/). Access: full_text_partial.

## Polymerase-independent developmental priming with an exception
Provider did not retrieve this original. Results2/4/7/12 show most early zebrafish opening persists under alpha-amanitin and precedes gene activation. Hypertranscribed miR430 loses opening, a specific exception. No universal statement that all accessibility requires transcription or that transcription is irrelevant is justified. [Original PMID31940339](https://pubmed.ncbi.nlm.nih.gov/31940339/). Access: full_text_partial.

## Catalytic-dead HAT separates opening from activation
Provider describes active-HAT bypass but omits the decisive control. Original Results7/8 show catalytic-dead dCas9-HAT restores asb11 opening without acetylation or transcription; active HAT rescues target transcription with untargeted/catalytic controls. HAT bypass does not mean opening itself is sufficient or bypassed. [Original PMID35182480](https://pubmed.ncbi.nlm.nih.gov/35182480/). Access: full_text_partial.

## Transcription-stage drugs and viable time windows
Original Results2/3/9/14 support paused RNAPII stabilizing BAF and ATPase-dependent nucleosome eviction. Triptolide shows no morphology/viability change up to2hours but defects at4hours, so early controlled evidence cannot license all late samples. PRC2-repressed and H3K9me3 constitutive regions differ. [Original PMID38049663](https://pubmed.ncbi.nlm.nih.gov/38049663/). Access: full_text_partial.

## Acute BRG1 interpretation and changed-site denominator
Original Results0/2/7/14 confirm endogenous AID baseline controls, nascent versus stable-RNA differences, and cross-cell-state experiments. Provider's96%figure concerns changed DHSs, not every DHS in the genome. Drug-treatment text and figure captions differ between10and12hours; no invented unified time is used. [Original PMID38811575](https://pubmed.ncbi.nlm.nih.gov/38811575/). Access: full_text_partial.

## Fast ATAC effects versus early transcription and tag baseline
Provider omitted this original. Actual Results0/1/5/6 verify rapid degron/inhibitor effects and nontoxic inhibitor controls, but the dTAG clone starts with approximately50%SMARCA4 and altered baseline. Few strong early PRO-seq changes do not demonstrate immediate global transcription loss or refute later dependency. [Original PMID33558760](https://pubmed.ncbi.nlm.nih.gov/33558760/). Access: full_text_partial.

## Reporter activity within accessible regions
Original abstract verifies roughly101000accessible regions and30%containing an activator, silencer or both. Provider numbers are retained only as the reporter assay's result. The remaining70%are not proved incompetent endogenous loci, and accessible silencers need not activate their own genomic transcription. [Original PMID35858748](https://pubmed.ncbi.nlm.nih.gov/35858748/). Access: abstract_metadata.

## Pioneering versus enhancer activation and publication date
Original2023published abstract, rather than provider2022label, reports genetically validated Zelda-dependent priming and additional patterning-factor activation. This supports separate tiers; computational fit alone does not prove state causality. [Original PMID37557175](https://pubmed.ncbi.nlm.nih.gov/37557175/). Access: abstract_metadata.

## Methods
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.